Summary

The aspirin drugs market was valued for $1.3 billion in 2023 and is estimated to reach $1.8 billion by 2035, exhibiting a CAGR of 2.7% from 2024 to 2035. Aspirin, also known as acetylsalicylic acid, is a widely used nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties. It works by inhibiting cyclooxygenase (COX) enzymes, reducing prostaglandin production, which helps relieve pain, fever, and inflammation. In addition, aspirin acts as an antiplatelet agent, preventing blood clot formation, making it essential in cardiovascular disease prevention and stroke management. It is commonly used for conditions like headaches, arthritis, muscle pain, and heart attack prevention. Available in various formulations, including tablets and enteric-coated versions, aspirin is one of the most affordable and accessible drugs globally. However, prolonged use may cause gastrointestinal side effects, requiring cautious administration, especially in high-risk individuals.
Rise in prevalence of diseases and the growing geriatric population are significant factors contributing to the growth of the aspirin drug market. Rise in incidence of cardiovascular diseases, arthritis, migraines, and inflammatory conditions has led to rise in demand for aspirin as a primary or adjunct treatment. The aging population is particularly contributing to aspirin consumption, as older individuals are more susceptible to heart-related conditions. A survey conducted by the University of Michigan found that one in four adults aged 50–80 (25%) reported taking aspirin regularly (three or more days per week). Among older adults who use aspirin regularly, 57% did not report a history of cardiovascular disease, and 82% of them stated that they take aspirin to prevent an initial heart attack or stroke. This highlights the widespread use of aspirin among the elderly as a preventive measure, further boosting its market demand.
Moreover, technological advancements in drug delivery systems are playing a crucial role in enhancing aspirin’s adoption. Innovations such as enteric-coated aspirin formulations have been developed to reduce gastric irritation and improve patient compliance. Enteric-coated tablets help protect the stomach lining by ensuring the drug is released in the small intestine rather than the stomach, minimizing the risk of gastrointestinal side effects. In addition, introduction of flavored dosage forms has improved patient experience, particularly for individuals who find it difficult to tolerate the traditional bitter taste of aspirin. These advancements are making aspirin more user-friendly, expanding its adoption across various patient demographics.
Furthermore, availability of standard guidelines on aspirin use is another key driver supporting its market growth. Regulatory bodies and medical organizations provide evidence-based recommendations for the effective and safe use of aspirin in cardiovascular disease prevention, pain relief, and inflammation management. Healthcare professionals rely on these guidelines to prescribe aspirin appropriately, ensuring its widespread integration into clinical practice. Rise in prevalence of cardiovascular and arthritis diseases, rise in aging population, technological innovations in drug delivery, and well-defined medical guidelines drive the aspirin drug market, positioning it as a vital pharmaceutical product for both treatment and prevention.
The aspirin drug market is segmented into dosage form, application, distribution channel, and region. On the basis of dosage form, it is segmented into tablets, capsules, and others. On the basis of application, it is classified into pain relief, cardiovascular disease prevention, anti-inflammatory uses, and other applications. On the basis of distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Region-wise, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Bayer AG, Perrigo Company plc, Cardinal Health, Thermo Fisher Scientific Inc., Mayne Pharma Group Limited, Advacare Pharma Inc., Dexcel Pharma Limited, Hyloris Pharmaceuticals SA, Conical Pharmaceuticals, and Geri-Care Pharmaceuticals Corp. The key players have adopted product approval and clinical trials as key strategies for expansion of their product portfolio.
Key Benefits for Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the aspirin drugs market analysis from 2023 to 2035 to identify the prevailing aspirin drugs market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the aspirin drugs market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global aspirin drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Regulatory Guidelines
● Additional company profiles with specific to client's interest
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By Dosage Form
● Tablets
● Capsules
● Others
By Application
● Pain Relief
● Cardiovascular Disease Prevention
● Anti-inflammatory Uses
● Others
By Distribution Channel
● Hospital Pharmacies
● Retail Pharmacies
● Online Pharmacies
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Bayer AG
○ Perrigo Company plc
○ Cardinal Health
○ Thermo Fisher Scientific Inc.
○ Mayne Pharma Group Limited
○ Advacare Pharma Inc.
○ Dexcel Pharma Limited
○ Geri-Care Pharmaceuticals Corp.
○ Conical Pharmaceuticals
○ Hyloris Pharmaceuticals SA

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of diseases
3.4.1.2. Widespread Availability and Affordability of Aspirin
3.4.1.3. Increase in Awareness of Preventive Healthcare
3.4.2. Restraints
3.4.2.1. Availability of alternative medication
3.4.3. Opportunities
3.4.3.1. Rise in research and development (R&D) initiatives
CHAPTER 4: ASPIRIN DRUGS MARKET, BY DOSAGE FORM
4.1. Overview
4.1.1. Market size and forecast
4.2. Tablets
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Capsules
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: ASPIRIN DRUGS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Pain Relief
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cardiovascular Disease Prevention
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Anti-inflammatory Uses
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: ASPIRIN DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: ASPIRIN DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Dosage Form
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Dosage Form
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Dosage Form
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Dosage Form
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Dosage Form
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Dosage Form
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Dosage Form
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Dosage Form
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Dosage Form
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Dosage Form
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Dosage Form
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Dosage Form
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Dosage Form
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Dosage Form
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Dosage Form
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Dosage Form
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Dosage Form
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Dosage Form
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Dosage Form
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Dosage Form
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Dosage Form
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Dosage Form
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Dosage Form
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Bayer AG
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Perrigo Company plc
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Cardinal Health
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Thermo Fisher Scientific Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Mayne Pharma Group Limited
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Advacare Pharma Inc.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.7. Dexcel Pharma Limited
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Hyloris Pharmaceuticals SA
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Conical Pharmaceuticals
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Geri-Care Pharmaceuticals Corp.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio